Osthole exhibits anti-cancer property in rat glioma cells through inhibiting PI3K/Akt and MAPK signaling pathways

Cellular Physiology and Biochemistry

Volumn 32, Issue 6, 2013, Pages 1751-1760

  Ding, Daofang ^a   Wei, Songpu ^a   Song, Yi ^a   Li, Linghui ^a   Du, Guoqing ^a   Zhan, Hongsheng ^a   Cao, Yuelong ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Apoptosis; Glioma cell; MAPK; Osthole; PI3K Akt; Proliferation

Indexed keywords

GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; OSTHOLE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; CASPASE 3; CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAX; PROTEIN BCL 2; SURVIVIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; GLIOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; DOWN REGULATION; GLIOMA CELL LINE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION;

RATTUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COUMARINS; DOWN-REGULATION; GLIOMA; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS;

EID: 84893115589     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000356609     Document Type: Article

References (36)

1. Jansen M, Yip S, Louis DN: Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 2010;9:717-726.
2. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-2710.
3. You L, Feng S, An R, Wang XH: Osthole: a promising lead compound for drug discovery from a traditional Chinese medicine (TCM). Nat Prod Commun 2009;4:297-302.
4. Tang CH, Yang RS, Chien MY, Chen CC, Fu WM: Enhancement of bone morphogenetic protein-2 expression and bone formation by coumarin derivatives via p38 and ERK-dependent pathway in osteoblasts. Eur J Pharmacol 2008;579:40-49.
5. Okamoto T, Kobayashi T, Yoshida S: Synthetic derivatives of osthole for the prevention of hepatitis. Med Chem 2007;3:35-44.
6. Zheng Y, Lu M, Ma L, Zhang S, Qiu M, Ma X: Osthole Ameliorates Renal Ischemia-Reperfusion Injury by Inhibiting Inflammatory Response. Urol Int 2013;91:350-356.
7. Yao L, Lu P, Li Y, Yang L, Feng H, Huang Y, Zhang D, Chen J, Zhu D: Osthole relaxes pulmonary arteries through endothelial phosphatidylinositol 3-kinase/Akt-eNOS-NO signaling pathway in rats.Eur J Pharmacol 2013;699:23-32.
8. Matsuda H, Tomohiro N, Ido Y, Kubo M: Anti-allergic effects of cnidii monnieri fructus (dried fruits of Cnidium monnieri) and its major component, osthol. Biol Pharm Bull 2002;25:809-12.
9. Okamoto T, Yoshida S, Kobayashi T, Okabe S: Inhibition of concanavalin Ainduced mice hepatitis by coumarin derivatives. Jpn J Pharmacol 2001;85:95-97.
10. Yang LL, Wang MC, Chen LG, Wang CC: Cytotoxic activity of coumarins from the fruits of Cnidium monnieri on leukemia cell lines. Planta Med 2003;69:1091-1095.
11. Chou SY, Hsu CS, Wang KT, Wang MC, Wang CC: Antitumor effects of Osthol from Cnidium monnieri: an in vitro and in vivo study. Phytother Res 2007;21:226-30.
12. Yang D, Gu T, Wang T, Tang Q, Ma C: Effects of osthole on migration and invasion in breast cancer cells. Biosci Biotechnol Biochem 2010;74:1430-1434.
13. Kao SJ, Su JL, Chen CK, Yu MC, Bai KJ, Chang JH, Bien MY, Yang SF, Chien MH: Osthole inhibits the invasive ability of human lung adenocarcinoma cells via suppression of NF-κB-mediated matrix metalloproteinase-9 expression.Toxicol Appl Pharmacol 2012;261:105-115.
14. Okamoto T, Kobayashi T, Yoshida S: Chemical aspects of coumarin compounds for the prevention of hepatocellular carcinomas. Curr Med Chem Anticancer Agents 2005;5:47-51.
15. Ye Y, Han X, Guo B, Sun Z, Liu S: Combination treatment with platycodin D and osthole inhibits cell proliferation and invasion in mammary carcinoma cell lines. Environ Toxicol Pharmacol 2013;36:115-124.
16. Zhang L, Jiang G, Yao F, He Y, Liang G, Zhang Y, Hu B, Wu Y, Li Y, Liu H: Growth inhibition and apoptosis induced by osthole, a natural coumarin, in hepatocellular carcinoma. PLoS One 2012;7:e37865.
17. Dong XH, Zhang DS, Zhang L, Li W, Meng XY: Osthole improves synaptic plasticity in the hippocampus and cognitive function of Alzheimers disease rats via regulating glutamate. Neural Regen Res 2012;7:2325-2332.
18. He Y, Qu S, Wang J, He X, Lin W, Zhen H, Zhang X: Neuroprotective effects of osthole pretreatment against traumatic brain injury in rats. Brain Res 2012;1433:127-136.
19. Lin LW, Kuo YH, Hseu YC, Tsai CW, Hsieh MT, Chen SC, Wu CR: Osthole Improves Spatial Memory Deficits in Rats via Hippocampal α 1-Adrenergic and D 1 /D 2 Receptors. Evid Based Complement Alternat Med 2013;2013:273682.
20. Chen T, Liu W, Chao X, Qu Y, Zhang L, Luo P, Xie K, Huo J, Fei Z: Neuroprotective effect of osthole against oxygen and glucose deprivation in rat cortical neurons: involvement of mitogen-activated protein kinase pathway.Neuroscience 2011;183:203-211.
21. Mao X, Yin W, Liu M, Ye M, Liu P, Liu J, Lian Q, Xu S, Pi R: Osthole, a natural coumarin, improves neurobehavioral functions and reduces infarct volume and matrix metalloproteinase-9 activity after transient focal cerebral ischemia in rats. Brain Res 2011;1385:275-280.
22. Tang DZ, Hou W, Zhou Q, Zhang M, Holz J, Sheu TJ, Li TF, Cheng SD, Shi Q, Harris SE, Chen D, Wang YJ: Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. J Bone Miner Res 2010;25:1234-1245.
23. Xu X, Zhang Y, Qu D, Jiang T, Li S: Osthole induces G2/M arrest and apoptosis in lung cancer A549 cells by modulating PI3K/Akt pathway. J Exp Clin Cancer Res 2011;30:33.
24. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-5320.
25. Xu XM, Zhang Y, Qu D, Feng XW, Chen Y, Zhao L: Osthole suppresses migration and invasion of A549 human lung cancer cells through inhibition of matrix metalloproteinase-2 and matrix metallopeptidase-9 in vitro. Mol Med Rep 2012;6:1018-1022.
26. Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA: Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organicmolecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 2001;98:119-124.
27. Kondraganti S, Mohanam S, Chintala SK, Kin Y, Jasti SL, Nirmala C, Lakka SS, Adachi Y, Kyritsis AP, Ali-Osman F, Sawaya R, Fuller GN, Rao JS: Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res 2000;60:6851-6855.
28. Lakka SS, Rajan M, Gondi C, Yanamandra N, Chandrasekar N, Jasti SL, Adachi Y, Siddique K, Gujrati M, Olivero W, Dinh DH, Kouraklis G, Kyritsis AP, Rao JS: Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 2002;21:8011-8019.
29. Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
30. Holland EC: Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001;2:120-129.
31. Bleeker FE, Molenaar RJ, Leenstra S: Recent advances in the molecular understanding of glioblastoma. J Neurooncol 2012;108:11-27.
32. Tatevossian RG, Lawson AR, Forshew T, Hindley GF, Ellison DW, Sheer D: MAPK pathway activation and the origins of pediatric low-grade astrocytomas. J Cell Physiol 2010;222:509-514.
33. Balmanno K, Cook SJ: Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 2009;16:368-377.
34. Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK: Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol 2012;14:819-829.
35. Fan QW, Weiss WA: Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors. Methods Mol Biol 2012;821:349-359.
36. Luo J, Manning BD, Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-262.